All news is rigorously fact-checked and reviewed by leading blockchain experts and seasoned industry insiders.
- Helix, built on Injective, is now available on both the App Store and Play Store for mobile crypto trading.
- As the first decentralized CLOB DEX, Helix offers full on-the-go trading without relying on centralized platforms.
Helix has finally landed on mobile. The flagship DEX built on Injective is now available for download directly from the Apple App Store and Google Play Store. This means that users no longer have to sit in front of a computer screen to trade crypto. Open the app, log in, and you can buy, sell, and even place limit orders—all from the palm of your hand.
What makes Helix stand out is its approach based on the world’s first decentralized Central Limit Order Book (CLOB) model. Unlike most DEXs that rely on Automated Market Makers (AMM), the CLOB model provides more transparency and accurate price control, similar to the systems used by professional exchanges.
So if you prefer full control over price and volume, Helix could be a more appealing option. And the good news: now you can access all of this while having coffee at a cafe or on the commuter line.
JUST ANNOUNCED: Helix has gone mobile! 📱
The premier DEX built on Injective and the first truly decentralized CLOB is now live on the Apple App Store and the Google Play Store.
Buy, sell, trade and more on the go. pic.twitter.com/IbLlmNLaRR
— Helix 🧬 (@HelixApp_) June 26, 2025
Injective Expands Validator Ecosystem With New Institutional Moves
However, the launch of Helix for mobile is just one part of a larger story in the Injective ecosystem. In early June, BitGo—an institutional-scale crypto custodian—officially joined the Injective network as a validator. This move strengthens the presence of large institutions in decentralized blockchain infrastructure, something that was previously dominated by the developer community and independent validators.
On the other hand, we also note Canary Capital’s move to form a Delaware trust for the potential launch of an Injective staking ETF. Although not yet an official ETF, this legal structure is often considered an early stage before filing a Form S-1 or 19b-4 document with the US exchange authority. It can be said that this is not a step taken “just to try.”
Furthermore, Injective also received attention from the CNF in mid-June for featuring Zellic in the Validator Spotlight program. Zellic is known for their advanced security audits and their role in network governance.
In addition, they are also offering 0% commission for new delegators in a rebate program that is still running until the end of July. If you have ever felt that staking is complicated or not very profitable, this offer could be a reason to try delegation on Injective.
Of course, the presence of Helix in the form of a mobile application shows that Injective is not only about technical performance, but also about user convenience. This is a sensible move, especially considering that most crypto users today open their digital wallets more often from smartphones than laptops.
Meanwhile, as of the writing time, INJ is swapped hands at about $10.93, up 11.01% over the last 7 days, driving its market cap to surpass the $1 billion mark.
